Cargando…
Current perspectives on the optimal management of infantile hemangioma
Infantile hemangiomas (IHs) are the most common benign tumor of infancy. As our understanding of their pathobiology has evolved, treatment has become more focused and tailored to specifically treat IH while minimizing adverse effects. Propranolol has gained FDA approval as the first medical therapy...
Autores principales: | Grzesik, Peter, Wu, June K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774589/ https://www.ncbi.nlm.nih.gov/pubmed/29388636 http://dx.doi.org/10.2147/PHMT.S115528 |
Ejemplares similares
-
Management of Infantile Hemangiomas: Current Trends
por: Sethuraman, Gomathy, et al.
Publicado: (2014) -
Management of Infantile Hemangiomas
por: Reddy, Kavitha K
Publicado: (2014) -
Infantile Periocular Hemangioma
por: Tavakoli, Mehdi, et al.
Publicado: (2017) -
Update on infantile hemangioma
por: Jung, Hye Lim
Publicado: (2021) -
Propranolol in the Treatment of Infantile Hemangiomas
por: Tan, Xin, et al.
Publicado: (2021)